Huang Xuedan, Xu Mingzhu, Shirahata Tatsuya, Li Wei, Koike Kazuo, Kojima-Yuasa Akiko, Yuasa Isao, Kobayashi Yoshinori
a School of Pharmaceutical Sciences , Kitasato University , Tokyo , Japan.
b Faculty of Pharmaceutical Science , Toho University , Funabashi , Japan.
Nat Prod Res. 2018 Jun;32(12):1459-1462. doi: 10.1080/14786419.2017.1350664. Epub 2017 Jul 10.
There is no drug administration-approved therapy for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). In this study, eight compounds, gallic acid (1), methyl gallate (2), corilagin (3), 3,4,8,9,10-pentahydroxydibenzo[b,d]pyran-6-one (4), repandinin B (5), (Z)-3-hexenyl-β-D-glucopyranoside (6), (+)-lyoniresinol-3α-O-α-L-rhamnopyranoside (7) and mallophenol A (8) were isolated from the active fractions of Mallotus furetianus. Three compounds, (6, 7 and 8) revealed potent anti-steatosis activity in the oleic acid (OA)-induced steatosis cell model, with the minimum effective concentration of 0.05 (6), 0.0005 (7) and 0.0005 (8) μg/mL, which were much lower than the control compound, fibrate (72.4 μg/mL).
目前尚无药物管理部门批准的用于治疗非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)的疗法。在本研究中,从毛桐(Mallotus furetianus)的活性部位分离出8种化合物,即没食子酸(1)、没食子酸甲酯(2)、柯里拉京(3)、3,4,8,9,10-五羟基二苯并[b,d]吡喃-6-酮(4)、重瓣鼠李素B(5)、(Z)-3-己烯基-β-D-吡喃葡萄糖苷(6)、(+)-里诺雷斯醇-3α-O-α-L-鼠李糖苷(7)和马洛酚A(8)。其中3种化合物(6、7和8)在油酸(OA)诱导的脂肪变性细胞模型中显示出有效的抗脂肪变性活性,其最低有效浓度分别为0.05(6)、0.0005(7)和0.0005(8)μg/mL,远低于对照化合物非诺贝特(72.4 μg/mL)。